SGLT 2 INHIBITORS | Latest News RSS feed

SGLT 2 INHIBITORS - Latest News


EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk

BERLIN — The sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) improved glycemic control and weight in type 1 diabetes, but also increased ... read more

Year in Review: Diabetes

Back in September, the phase III DECLARE-TIMI 58 trial found that the SGLT-2 inhibitor dapagliflozin (Farxiga) significantly reduced the risk of hospitalization for heart failure or cardiovascular dea... read more

Lexicon Likely Looking At Even More Competition In Type 1 Diabetes

and off-label use of SGLT-2 inhibitors already approved for Type 2 diabetes. Lexicon could really use some good news, as the company has seen sentiment on sotagliflozin fade due to concerns about ... read more

Looking for another news?


EMPA-REG: Empagliflozin can add 4 years to life expectancy in diabetes with CVD

Adults with type 2 diabetes and established cardiovascular disease who take the SGLT2 inhibitor empagliflozin can expect to live between 1 and 5 years longer than those without the drug, depending on ... read more


Positive Results for Empagliflozin in Type 1 Diabetes Trials

Empagliflozin (Jardiance; Boehringer Ingelheim and Lilly), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is currently approved as an adjunct to diet and exercise to improve glycemic control in ... read more

SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia?

BERLIN – Use of diuretics may increase the risk for lower limb amputations in people with diabetes, and the same hypovolemic effect might help explain the increased risk of amputations seen with the s... read more

Neurocrine, Jnana team up to discover CNS drugs

Multiple companies have tried to drug the proteins—SGLT2 inhibitors being a recent example of a successful effort—but the therapeutic potential of the vast majority of SLCs remains untapped and undere... read more

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sod... read more

SGLT2 Inhibitors Market Current and Projected size in terms of volume and value 2016-2024

Sodium glucose transporters are proteins responsible for reabsorption of glucose from kidneys. This protein family has two members: sodium glucose cotransporter-1 (SGLT1) and sodium glucose cotranspor... read more

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * MER... read more

Antisense Lp(a) Agent; Overdose Drug with AEDs; Mixed CV Results for T2D Drug

The SGLT2 inhibitor dapagliflozin (Farxiga) failed to reduce major cardiovascular events compared with placebo in the DECLARE-TIMI-58 cardiovascular outcomes trial in type 2 diabetes but did meet noni... read more

SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes

SAN DIEGO, June 13, 2017 /PRNewswire-USNewswire/ -- A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us